Overview

A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of bimatoprost 0.01% in subjects with elevated intraocular pressure (IOP) due to primary open-angle glaucoma (POAG) or ocular hypertension (OH).
Phase:
Phase 4
Details
Lead Sponsor:
Allergan
Treatments:
Bimatoprost